Based in Cambridge UK, Qureight, a core imaging laboratory has been making significant progress since their inception in 2018. It has forged meaningful partnerships with pharma, biotech and contract research organisations. Their proprietary technology is accelerating lung and heart drug development using AI-powered imaging and data curation to optimize trial endpoints and patient stratification. The company also has a broader vision to explore rare and autoimmune diseases.

Damian Doherty, editor in chief of Inside Precsion Medicine , spoke with Simon Walsh Chief Scientific Officer at Qureight to explore the company’s powerful cutting-edge AI technology and its transformative potential. From lung and heart disease to broader applications, Walsh shares how Qureight aims to revolutionize

See Full Page